All News

Microvascular CV Disease with Severe Psoriasis

Save

d Jack Cush, MD

Sep 26, 2023

While comorbidities, including an increased cardiovascular (CV) risk, are associated with severe psoriasis, less is known about subclinical CV disease and when it occurs in patients with psoriasis.

Read Article

Machine Learning May Diagnose Psoriatic Arthritis Earlier A machine learning approach was applied to two different population cohorts and was shown to be effective at the early identification of undiagnosed psoriatic arthritis (PsA). https://t.co/ecAF5OTgfr https://t.co/9R2ZZH3I7j

RheumNow Dr. John Cush ( View Tweet)

Sep 24, 2023

RheumNow Podcast with Special Guest Dr. Michael Weinblatt (9.22.2023)

Save

d Jack Cush, MD

Sep 22, 2023

Dr. Jack Cush is joined by Dr. Michael Weinblatt as they discuss this weeks news and journal reports, including difficult RA, HLA typing and abatacept responses and new regulatory decisions.

Read Article

Machine Learning May Diagnose Psoriatic Arthritis Earlier

Save

d Jack Cush, MD

Sep 18, 2023

A machine learning approach was applied to two different population cohorts and was shown to be effective at the early identification of undiagnosed psoriatic arthritis (PsA).

Read Article

SAVE THE DATE! RheumNow Live will now be taking place in January! Who is joining us? https://t.co/EdrLp87Z81

RheumNow Dr. John Cush ( View Tweet)

Sep 09, 2023

Woeful Rheumatology Referrals

Save

d Jack Cush, MD

Sep 07, 2023

Early diagnosis of inflammatory arthritis (IA) is rooted in patient (self or MD) referrals. A recent analysis shows only a minority of rheumatology referrals had inflammatory arthritis, with only 21% were seen within the first 6 weeks of symptoms.

Read Article

SAVE THE DATE! RheumNow Live will now be taking place in January! Will you be there? https://t.co/cpfWvKaR1y

RheumNow Dr. John Cush ( View Tweet)

Sep 02, 2023

UK regulatory authority (MHRA) has granted marketing authorization for Bimzelx (bimekizumab), a dual inhibitor of IL-17A & IL-17F; approved in adults w/ active psoriatic arthritis or axial spondyloarthritis (+/- MTX). Prev approved in EU June 2023 https://t.co/Hp5W1t6Acz https://t.co/6tZ1DN8TVo

RheumNow Dr. John Cush ( View Tweet)

Sep 01, 2023

SAVE THE DATE! RheumNow Live will now be taking place in January! Will you be there? https://t.co/WCfBzthXvl

RheumNow Dr. John Cush ( View Tweet)

Aug 31, 2023

COSMOS: Guselkumab's Immunologic Benefits in Psoriatic Arthritis https://t.co/tFquWoITSn https://t.co/7vQl2a6Vvu

Links:

https://bit.ly/45zlzwp

Dr. John Cush RheumNow ( View Tweet)

Aug 21, 2023

PRESTO Tool Predicts the Risk of PsA In research published in Arthritis & Rheumatology, investigators developed called PRESTO that identifies patients with psoriasis who face an elevated risk for developing pSa and may benefit from preventive therapies. https://t.co/hp8ygab41B https://t.co/EvMcabQJjd

Links:

https://bit.ly/3sbJOT0

Dr. John Cush RheumNow ( View Tweet)

Aug 19, 2023

COSMOS: Guselkumab's Immunologic Benefits in Psoriatic Arthritis

Save

d Jack Cush, MD

Aug 17, 2023

The IL-23 inhibitor guselkumab was studied in active psoriatic arthritis patients in the phase 3b COSMOS trial, and shown to be clinically effective while reducing multiple effector cytokines, including those associated with the IL-23/IL-17 pathway.

Read Article

UK study of 1,.3 million RMD (RA, PsA, FM) pts looked at opioid Rx 2006-2021. New opioid Rx incr 2006 to 2019, but incr most (4.5 fold) in FM from 3.4/10K in 2006 to 8.7 in 2018/2019 (falling to 5.9 in 2021). Overall less opioid use during the pandemic https://t.co/rNmk6AGMAX https://t.co/8XDFjFa5x9

Links:

https://bit.ly/3QYXNpV

Dr. John Cush RheumNow ( View Tweet)

Aug 16, 2023

The Adalimumab Biosimilar Glut

Save

d Jack Cush, MD

Aug 15, 2023

In 2023, three marketed biosimilars (Actemra, Stelara, Humira) had their patents expire, opening opportunities for multiple new biosimilars; but with competition comes a word salad of new drug names, confusion and nonsensical discounts.

Read Article

Links:

https://bit.ly/3YAVTO0

Dr. John Cush RheumNow ( View Tweet)

Aug 14, 2023

Pizza and Rheumatoid Arthritis (8.11.2023)

Save

d Jack Cush, MD

Aug 11, 2023

Dr. Jack Cush reviews the news and journal reports from the wonderful wide world of Rheumatology. This week:

Read Article

Patient Perspectives on Telemedicine Use During the Pandemic Research from the COVID-19 Global Rheumatology Alliance included surveys and data gathering from rheumatology patients. https://t.co/EJ5TkiDMcJ https://t.co/xBx7OIxf9h

Links:

https://bit.ly/45lemA9

Dr. John Cush RheumNow ( View Tweet)

Aug 10, 2023

PRESTO Tool Predicts the Risk of Psoriatic Arthritis

Save

d EurekAlert!

Aug 09, 2023

In research published in Arthritis & Rheumatology, investigators developed and validated a tool called PRESTO that identifies p

Read Article

Assessment of Psoriatic Arthritis: A Global Perspective Drs. Antoni Chan, Nelly Ziade and Ihsane Hmamouchi discuss POS1542 presented at EULAR 2023 in Milan, Italy https://t.co/mSNhAma78C https://t.co/dhikAgIW7t

Links:

https://bit.ly/44Vezdj

Dr. John Cush RheumNow ( View Tweet)

Aug 08, 2023

HEALTH DISPARITIES: Lancet study shows from 2000-2019, all-cause mortality was signif. higher in the American Indian/Alaska Native (1028/100K) & Blacks (953·/100K) compared to Whites (802); but lower in Asians (442) & Latinos (595) https://t.co/g8Z3h6BYw8 https://t.co/Ckz1L3O0W7

Links:

https://bit.ly/45eZ67L

Dr. John Cush RheumNow ( View Tweet)

Aug 04, 2023

Topics

All News

Microvascular CV Disease with Severe Psoriasis

Save

RheumNow Podcast with Special Guest Dr. Michael Weinblatt (9.22.2023)

Save

Machine Learning May Diagnose Psoriatic Arthritis Earlier

Save

Woeful Rheumatology Referrals

Save

COSMOS: Guselkumab's Immunologic Benefits in Psoriatic Arthritis

Save

The Adalimumab Biosimilar Glut

Save

Pizza and Rheumatoid Arthritis (8.11.2023)

Save

PRESTO Tool Predicts the Risk of Psoriatic Arthritis

Save

Do you get our email newsletter?